Tool for screening immune therapeutics; bench mark therapeutics in an immune check point inhibitor (Pembrolizumab) sensitive assay or ADCC

Dr Rhiannon Jenkinson (CSO) and Jody Sawyer (VP of Business Development) showcased our services spanning preclinical screening, efficacy, translational models, predictive immunotoxicology and clinical Biomarkers, within the IO, Autoimmunity and Inflammatory space. Connecting with our current clients and meeting new ones. We will be back in 2024, continuing to support companies within the west coast Biotech hubs. Watch our Events page to see when we are visiting or Contact Us in the meantime to see how we can help.

Dr Rhiannon Jenkinson (CSO) and Jody Sawyer (VP of Business Development) had a fantastic time at the IO conference in Boston, meeting with current clients and new companies. After spending time at the conference, visiting the Boston Biotech hub and dining with clients the Nexus BioQuest team were extremely grateful for the fruitful discussions and excited about future collaborations. The Nexus Team will be back in Boston in early 2024 to visit clients and later in the year for the Special AACR conference, see more on our Events page. If you are interested in meeting the team in March 2024 Contact Us

Accelerate the buying process by finding Nexus BioQuest as a supplier on Science Exchange Science Exchange | Supplier Orchestration | R&D Marketplace and Scientist.com World’s Leading AI-Powered R&D Marketplace | Scientist.com